Literature DB >> 15517152

A model to estimate the lifetime health outcomes of patients with type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS) Outcomes Model (UKPDS no. 68).

P M Clarke1, A M Gray, A Briggs, A J Farmer, P Fenn, R J Stevens, D R Matthews, I M Stratton, R R Holman.   

Abstract

AIMS/HYPOTHESIS: The aim of this study was to develop a simulation model for type 2 diabetes that can be used to estimate the likely occurrence of major diabetes-related complications over a lifetime, in order to calculate health economic outcomes such as quality-adjusted life expectancy.
METHODS: Equations for forecasting the occurrence of seven diabetes-related complications and death were estimated using data on 3642 patients from the United Kingdom Prospective Diabetes Study (UKPDS). After examining the internal validity, the UKPDS Outcomes Model was used to simulate the mean difference in expected quality-adjusted life years between the UKPDS regimens of intensive and conventional blood glucose control.
RESULTS: The model's forecasts fell within the 95% confidence interval for the occurrence of observed events during the UKPDS follow-up period. When the model was used to simulate event history over patients' lifetimes, those treated with a regimen of conventional glucose control could expect 16.35 undiscounted quality-adjusted life years, and those receiving treatment with intensive glucose control could expect 16.62 quality-adjusted life years, a difference of 0.27 (95% CI: -0.48 to 1.03). CONCLUSIONS/INTERPRETATIONS: The UKPDS Outcomes Model is able to simulate event histories that closely match observed outcomes in the UKPDS and that can be extrapolated over patients' lifetimes. Its validity in estimating outcomes in other groups of patients, however, remains to be evaluated. The model allows simulation of a range of long-term outcomes, which should assist in informing future economic evaluations of interventions in type 2 diabetes.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15517152     DOI: 10.1007/s00125-004-1527-z

Source DB:  PubMed          Journal:  Diabetologia        ISSN: 0012-186X            Impact factor:   10.122


  32 in total

1.  Probability of stroke: a risk profile from the Framingham Study.

Authors:  P A Wolf; R B D'Agostino; A J Belanger; W B Kannel
Journal:  Stroke       Date:  1991-03       Impact factor: 7.914

2.  Comparison of baseline and repeated measure covariate techniques in the Framingham Heart Study.

Authors:  L A Cupples; R B D'Agostino; K Anderson; W B Kannel
Journal:  Stat Med       Date:  1988 Jan-Feb       Impact factor: 2.373

3.  Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64).

Authors:  Amanda I Adler; Richard J Stevens; Sue E Manley; Rudy W Bilous; Carole A Cull; Rury R Holman
Journal:  Kidney Int       Date:  2003-01       Impact factor: 10.612

4.  Lifetime benefits and costs of intensive therapy as practiced in the diabetes control and complications trial. The Diabetes Control and Complications Trial Research Group.

Authors: 
Journal:  JAMA       Date:  1996-11-06       Impact factor: 56.272

Review 5.  Practical problems in fitting a proportional hazards model to data with updated measurements of the covariates.

Authors:  D G Altman; B L De Stavola
Journal:  Stat Med       Date:  1994-02-28       Impact factor: 2.373

6.  Cost effectiveness of an intensive blood glucose control policy in patients with type 2 diabetes: economic analysis alongside randomised controlled trial (UKPDS 41). United Kingdom Prospective Diabetes Study Group.

Authors:  A Gray; M Raikou; A McGuire; P Fenn; R Stevens; C Cull; I Stratton; A Adler; R Holman; R Turner
Journal:  BMJ       Date:  2000-05-20

7.  Assessing the impact of complications on the costs of Type II diabetes.

Authors:  R Williams; L Van Gaal; C Lucioni
Journal:  Diabetologia       Date:  2002-06-12       Impact factor: 10.122

8.  Gains in life expectancy from medical interventions--standardizing data on outcomes.

Authors:  J C Wright; M C Weinstein
Journal:  N Engl J Med       Date:  1998-08-06       Impact factor: 91.245

9.  UK Prospective Diabetes Study (UKPDS). VIII. Study design, progress and performance.

Authors: 
Journal:  Diabetologia       Date:  1991-12       Impact factor: 10.122

10.  Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group.

Authors: 
Journal:  Lancet       Date:  1998-09-12       Impact factor: 79.321

View more
  200 in total

1.  Intensified glucose lowering in type 2 diabetes: time for a reappraisal.

Authors:  J S Yudkin; B Richter; E A M Gale
Journal:  Diabetologia       Date:  2010-08-05       Impact factor: 10.122

2.  Management of hypertension: Regional variations in a greatly improved landscape.

Authors:  Sheldon W Tobe
Journal:  Can J Cardiol       Date:  2010-10       Impact factor: 5.223

3.  End-stage renal disease risk equations for Hong Kong Chinese patients with type 2 diabetes: Hong Kong Diabetes Registry.

Authors:  X L Yang; W Y So; A P S Kong; P Clarke; C S Ho; C W K Lam; M H L Ng; R R Lyu; D D Yin; C C Chow; C S Cockram; P C Y Tong; J C N Chan
Journal:  Diabetologia       Date:  2006-08-30       Impact factor: 10.122

4.  Long-Term Impact of an Electronic Health Record-Enabled, Team-Based, and Scalable Population Health Strategy Based on the Chronic Care Model.

Authors:  Kensaku Kawamoto; Kevin J Anstrom; John B Anderson; Hayden B Bosworth; David F Lobach; Carrie McAdam-Marx; Jeffrey M Ferranti; Howard Shang; Kimberly S H Yarnall
Journal:  AMIA Annu Symp Proc       Date:  2017-02-10

5.  An innovative model for changing the lifestyles of persons with obesity and/or Type 2 diabetes mellitus.

Authors:  P De Feo; C Fatone; P Burani; N Piana; C Pazzagli; D Battistini; D Capezzali; R Pippi; B Chipi; C Mazzeschi
Journal:  J Endocrinol Invest       Date:  2011-07-12       Impact factor: 4.256

6.  Economic evidence at the local level : options for making it more useful.

Authors:  Kees van Gool; Gisselle Gallego; Marion Haas; Rosalie Viney; Jane Hall; Robyn Ward
Journal:  Pharmacoeconomics       Date:  2007       Impact factor: 4.981

7.  Metabolic effects of interventions to increase exercise in adults with type 2 diabetes.

Authors:  V S Conn; A R Hafdahl; D R Mehr; J W LeMaster; S A Brown; P J Nielsen
Journal:  Diabetologia       Date:  2007-03-07       Impact factor: 10.122

8.  Estimating the cost of diabetes mellitus-related events from inpatient admissions in Sweden using administrative hospitalization data.

Authors:  Ulf-G Gerdtham; Philip Clarke; Alison Hayes; Soffia Gudbjornsdottir
Journal:  Pharmacoeconomics       Date:  2009       Impact factor: 4.981

Review 9.  The place of DPP-4 inhibitors in the treatment algorithm of diabetes type 2: a systematic review of cost-effectiveness studies.

Authors:  Alexandre Baptista; Inês Teixeira; Sónia Romano; António Vaz Carneiro; Julian Perelman
Journal:  Eur J Health Econ       Date:  2016-10-17

10.  Simulating lifetime outcomes associated with complications for people with type 1 diabetes.

Authors:  Tom W C Lung; Philip M Clarke; Alison J Hayes; Richard J Stevens; Andrew Farmer
Journal:  Pharmacoeconomics       Date:  2013-06       Impact factor: 4.981

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.